385 reports of this reaction
2.0% of all DEXAMETHASONE SODIUM PHOSPHATE reports
#10 most reported adverse reaction
MYELOSUPPRESSION is the #10 most commonly reported adverse reaction for DEXAMETHASONE SODIUM PHOSPHATE, manufactured by Amneal Pharmaceuticals LLC. There are 385 FDA adverse event reports linking DEXAMETHASONE SODIUM PHOSPHATE to MYELOSUPPRESSION. This represents approximately 2.0% of all 19,106 adverse event reports for this drug.
Patients taking DEXAMETHASONE SODIUM PHOSPHATE who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is a less commonly reported adverse event for DEXAMETHASONE SODIUM PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to myelosuppression, the following adverse reactions have been reported for DEXAMETHASONE SODIUM PHOSPHATE:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 385 FDA reports for DEXAMETHASONE SODIUM PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 2.0% of all adverse event reports for DEXAMETHASONE SODIUM PHOSPHATE, making it a notable side effect.
If you experience myelosuppression while taking DEXAMETHASONE SODIUM PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.